GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Shares Buyback Ratio %

CDMO (Avid Bioservices) Shares Buyback Ratio % : -1.14 (As of Dec. 13, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices Shares Buyback Ratio %?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Avid Bioservices's current shares buyback ratio was -1.14%.

Avid Bioservices Shares Buyback Ratio % Historical Data

The historical data trend for Avid Bioservices's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avid Bioservices Shares Buyback Ratio % Chart

Avid Bioservices Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.62 -8.12 -1.21 -1.43 -1.40

Avid Bioservices Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.19 -0.36 -0.17 -0.35 -0.26

Avid Bioservices Shares Buyback Ratio % Calculation

Avid Bioservices's Shares Buyback Ratio for the fiscal year that ended in Apr. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Apr. 2023 ) - Shares Outstanding (EOP) (A: Apr. 2024 )) / Shares Outstanding (EOP) (A: Apr. 2023 )
=(62.6919 - 63.568) / 62.6919
=-1.40%

Avid Bioservices's Shares Buyback Ratio for the quarter that ended in Oct. 2024 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Jul. 2024 ) - Shares Outstanding (EOP) (A: Oct. 2024 )) / Shares Outstanding (EOP) (A: Jul. 2024 )
=(63.79 - 63.956) / 63.79
=-0.26%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avid Bioservices Shares Buyback Ratio % Related Terms

Thank you for viewing the detailed overview of Avid Bioservices's Shares Buyback Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Avid Bioservices Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Shares Buyback Ratio %
Comparable Companies
PRTA PLRX AUTL SLNCF RLAY AVXL TYRA ERAS ABCL CRGX VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
TEHN:Germany
Address
14191 Myford Road, Tustin, CA, USA, 92780
Website
https://www.avidbio.com
Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. Its business is organized into one reportable operating segment which is contract manufacturing and development services segment. Its services include clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The company also provides a variety of process development services including cell line development, upstream and downstream development and optimization, analytical method development, testing and characterization.
Executives
Matthew R. Kwietniak officer: Chief Commercial Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri officer: Chief Operations Officer 14191 MYFORD ROAD, TUSTIN CA 92780
Nicholas Stewart Green director, officer: President & CEO 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Daniel Ryan Hart officer: Chief Financial Officer 2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell officer: V.P., General Counsel 14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock director 14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone director 3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Gregory Sargen director
Esther M. Alegria director 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth director 500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma director C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg officer: Principal Fin. & Acct. Officer 2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780